Tebentafusp can bind the gp100 protein presented on HLA-A*02 via its T cell receptor domain with a high affinity, while its anti-CD3 antibody domain binds surveilling CD3+ T cells to generate an immune response against the melanoma cells. This evidence concerns the gene PMEL and melanoma.